Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPRC | P08575 | 2/20 | 0.76 |
| ▸ | CES1 | P23141 | 2/20 | 0.62 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.58 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.58 |
| ▸ | MEN1 | O00255 | 3/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.55 |
| ▸ | CDC25B | P30305 | 1/20 | 0.55 |
| ▸ | TERT | O14746 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | CES2 | O00748 | 1/20 | 0.46 |
| ▸ | APAF1 | O14727 | 1/20 | 0.46 |
| ▸ | PLIN1 | O60240 | 1/20 | 0.46 |
| ▸ | TDP2 | O95551 | 1/20 | 0.46 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.46 |
| ▸ | BCHE | P06276 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9673985 | 0.91 | PTPRC (0.91) | PTPRCCES1PABPC1DNMT1MEN1 | |
| SCHEMBL7318972 | 0.91 | CES1 (0.70) | PTPRCCES1PABPC1DNMT1MEN1 | |
| SCHEMBL31141849 | 0.91 | PTPRC (0.91) | PTPRCCES1PABPC1DNMT1MEN1 | |
| SCHEMBL206335 | 0.88 | CES1 (0.79) | PTPRCCES1PABPC1DNMT1 | |
| SCHEMBL4051230 | 0.86 | PTPRC (1.00) | PTPRCCES1PABPC1DNMT1MEN1 | |
| SCHEMBL6995084 | 0.85 | CES1 (0.75) | PTPRCCES1PABPC1DNMT1MEN1 | |
| SCHEMBL9674046 | 0.83 | CES1 (0.71) | PTPRCCES1PABPC1DNMT1 | |
| SCHEMBL29915354 | 0.83 | CES1 (0.71) | PTPRCCES1PABPC1DNMT1 | |
| SCHEMBL2111492 | 0.83 | CES1 (0.70) | PTPRCCES1PABPC1DNMT1MEN1 | |
| SCHEMBL10051615 | 0.80 | CES1 (0.60) | PTPRCCES1PABPC1DNMT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025058297-A1 | COMPOSITION FOR PREVENTING OR TREATING CANCER, COMPRISING STAT3 INHIBITOR AND NICLOSAMIDE | 국립암센터 | 2025-03-20 | — | — | WO | claimed |
| WO-2025058297-A1 | COMPOSITION FOR PREVENTING OR TREATING CANCER, COMPRISING STAT3 INHIBITOR AND NICLOSAMIDE | 국립암센터 | 2025-03-20 | — | — | WO | disclosed |
| US-20190015379-A1 | USE OF DIANHYDROGALACTITOL AND ANALOGS AND DERIVATIVES THEREOF, TOGETHER WITH RADIATION, TO TREAT NON-SMALL-CELL CARCINOMA OF THE LUNG AND GLIOBLASTOMA MULTIFORME AND SUPPRESS PROLIFERATION OF CANCER STEM CELLS | DEL MAR PHARMACEUTICALS (BC) LTD. (CA) | 2019-01-17 | — | — | US | disclosed |
| EP-3217970-A1 | DIANHYDROGALACTITOL TOGETHER WITH RADIATION TO TREAT NON-SMALL-CELL CARCINOMA OF THE LUNG AND GLIOBLASTOMA MULTIFORME | Del Mar Pharmaceuticals (CA) | 2017-09-20 | — | — | EP | disclosed |
| WO-2016077264-A1 | DIANHYDROGALACTITOL TOGETHER WITH RADIATION TO TREAT NON-SMALL-CELL CARCINOMA OF THE LUNG AND GLIOBLASTOMA MULTIFORME | DEL MAR PHARMACEUTICALS (CA) | 2016-05-19 | — | — | WO | disclosed |
| US-9312501-B2 | Semiconducting compounds and optoelectronic devices incorporating same | POLYERA CORPORATION (US) | 2016-04-12 | — | — | US | disclosed |
| US-9312501-B2 | Semiconducting compounds and optoelectronic devices incorporating same | POLYERA CORPORATION (US) | 2016-04-12 | — | — | US | disclosed |
| US-9312501-B2 | Semiconducting compounds and optoelectronic devices incorporating same | POLYERA CORPORATION (US) | 2016-04-12 | — | — | US | disclosed |
| US-8871802-B2 | Naphthoquinones for disease therapies | ZHOUSHAN HAIZHONGZHOU XINSHENG PHARMACEUTICALS CO., LTD. (CN) | 2014-10-28 | — | — | US | disclosed |
| US-8871802-B2 | Naphthoquinones for disease therapies | ZHOUSHAN HAIZHONGZHOU XINSHENG PHARMACEUTICALS CO., LTD. (CN) | 2014-10-28 | — | — | US | disclosed |
| EP-1093456-B1 | NAPHTHO- AND DIHYDROBENZO-THIOPHENE DERIVATIVES AS CYTOTOXIC ANTITUMOR AGENTS | UNIV NORTH CAROLINA (US) | 2003-12-17 | — | — | EP | disclosed |
| US-6337346-B1 | BENZODITHIOPHENE DERIVATIVES | UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL | 2002-01-08 | — | — | US | disclosed |
| EP-1093456-A2 | NAPHTHO- AND DIHYDROBENZO-THIOPHENE DERIVATIVES AS CYTOTOXIC ANTITUMOR AGENTS | UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2001-04-25 | — | — | EP | disclosed |
| US-6174913-B1 | TREATING TUMOR BY ADMINISTERING COMPOUNDS E.G.:2-ACETYL-NAPHTHO(2,3-B)THIOPHENE-4,9-DIONE; 2,7-DIACETYL-NAPHTHO(2,3-B)THIOPHENE-4,9-DIONE | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL | 2001-01-16 | — | — | US | disclosed |
| WO-1999062909-A9 | NAPHTHO- AND DIHYDROBENZO-THIOPHENE DERIVATIVES AS CYTOTOXIC ANTITUMOR AGENTS | UNIV NORTH CAROLINA (US) | 2000-04-27 | — | — | WO | disclosed |
| WO-1999062909-A2 | NAPHTHO- AND DIHYDROBENZO-THIOPHENE DERIVATIVES AS CYTOTOXIC ANTITUMOR AGENTS | UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 1999-12-09 | — | — | WO | disclosed |
| EP-0095340-B1 | PROCESSES FOR MAKING 3-METHYLTHIOPHENE-2-CARBOXALDEHYDE AND INTERMEDIATES THEREFOR | PFIZER INC. (US) | 1986-08-13 | — | — | EP | disclosed |
| US-4476312-A | Processes for making 3-methylthiophene-2-carboxaldehyde and intermediates therefor | PFIZER INC. (US) | 1984-10-09 | — | — | US | disclosed |
| US-4471139-A | Processes for making 3-methylthiophene-2-carboxaldehyde and intermediates therefor | PFIZER INC. (US) | 1984-09-11 | — | — | US | disclosed |
| EP-0095340-A1 | Processes for making 3-methylthiophene-2-carboxaldehyde and intermediates therefor | PFIZER INC. (US) | 1983-11-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190015379-A1 | USE OF DIANHYDROGALACTITOL AND ANALOGS AND DERIVATIVES THEREOF, TOGETHER WITH RADIATION, TO TREAT NON-SMALL-CELL CARCINOMA OF THE LUNG AND GLIOBLASTOMA MULTIFORME AND SUPPRESS PROLIFERATION OF CANCER STEM CELLS | MGMT, DCLRE1A, DNMT1 | PTPRC 3210/4885CES1 2517/4885PABPC1 2335/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.